'Having led multiple therapeutics and healthcare organizations as CEO, Steven brings an exceptional track record as an executive to the Board of Directors here at DermBiont, the world's leading skin microbiome therapeutics company. Our entire leadership team is excited to benefit from his experience as we continue to advance our discovery programs and products in development,' said
'DermBiont has built an incredible platform and culture that enables the company to discover and advance microbial therapeutics through the clinic much faster and more efficiently than traditional therapeutics,' said
DermBiont's other current board members are:
About DermBiont
DermBiont is the world's leading dermatology company leveraging skin microbiome therapeutics (live biotherapeutics) to treat the root cause of skin diseases. In addition to the company's lead product in development to treat Onychomycosis and Atopic Dermatitis, DBI-001, the company is advancing four other clinical assets across a wide range of skin diseases caused by a dysbiosis of the microbiome. The company's discovery capabilities are powered by a proprietary computational biology platform enabling the rapid discovery of hits against pathogens from a curated library of thousands of microbes isolated from human skin and one of the world's largest data sets of Nextgen sequencing of the human microbiome across healthy and diseased skin.
Contact:
Email: press@dermbiont.com
Web: http://www.dermbiont.com
(C) 2020 Electronic News Publishing, source